Welcome Guest

Analysis: Drugmakers see a pricing blueprint in an $850,000 gene therapy

reuters | Posted on 2018-01-13 09:26 AM

SAN FRANCISCO (Reuters) - Global drugmakers are looking to a tiny biotech's $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines.

Related Articles

  • Live
  • Upcomming
  • Completed